Keyphrases
Antifibrotic
100%
Myelofibrosis
100%
Hepatocyte Growth Factor
80%
Primary Myelofibrosis
60%
Captopril
40%
Factor Level
40%
Fibrocytes
20%
Compensatory Response
20%
Bone Marrow Microenvironment
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Gain-of-function mutation
20%
Heart-kidney
20%
Lung
20%
Fibrosis
20%
Tissue Repair
20%
Ruxolitinib
20%
GATA1
20%
Liver
20%
MPLW515L
20%
Myeloproliferative Neoplasms
20%
JAK2V617F
20%
Fibrotic Diseases
20%
Life-threatening
20%
Mouse Model
20%
Specific Intent
20%
Beneficial Effects
20%
Marrow Fibrosis
20%
Medicine and Dentistry
Myelofibrosis
100%
Scatter Factor
80%
Myeloid metaplasia
60%
Fibrosis
40%
Captopril
40%
Disease
40%
Bone Marrow Microenvironment
20%
Gain of Function Mutation
20%
Ruxolitinib
20%
Prevalence
20%
Transcription Factor GATA 1
20%
Allogeneic Stem Cell Transplantation
20%
Myeloproliferative Neoplasm
20%
Tissue Repair
20%
Lung
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
100%
Scatter Factor
80%
Myeloid metaplasia
60%
Captopril
40%
Fibrosis
40%
Prevalence
20%
Transcription Factor GATA 1
20%
Mouse Model
20%
Tissue Repair
20%
Myeloproliferative Neoplasm
20%
Ruxolitinib
20%
Diseases
20%